Intra-Cellular Therapies Reports Net Loss of $86.8 Million for the Second Quarter of 2023
The company's revenue reaches $110.8 million, driven by strong product sales and grants.
By USInMinutes
Published - Aug 04, 2023, 03:18 PM ET
Last Updated - Aug 04, 2023, 03:18 PM EDT
Intra-Cellular Therapies, Inc.(ITCI) and Subsidiary released their finan cial results for the second quarter of 2023, revealing a net loss of $86.8 million. However, the company also reported impressive revenues of $110.8 million for the same period, attributed to strong product sales and grant revenue.
Net Loss of $86.8 Million in Q2 2023
The company faced a net loss of $86.8 million for the three months ended June 30, 2023. This result highlights the financial challenges the company has encountered during this quarter.
Revenue Surges to $110.8 Million
